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Ferritin， carcinoembryonic antigen (CEA) and s，-microg10bulin (s2・MG)1evels in urine from 
45 patients with cancer (4 with renal adenocarcinoma， 7 with renal pelvic and uretera1 cancer and 
34 with bladder cancer) at various stages were clinically evaluated for their significa即 eas parameter 
of urinary tract malignancies as compared to urinary fibrin{fibrinogen degradation products (FDP) 
and urine cyt010gy. 
Ferritin levels for the poorly-differentiated and advanced stage groups were higher than those 
for the weIl-differentiated and early stage groups， and were especiaIly high in 5 of the 7 patients with 
renal pelvic and ureteral cancer and all of the 7 patients with bladder cancer involving the upper 
urinary tract. These data suggest that determination of urinary ferritin is useful in the detection 
of urinary tract cancer involving the upper urinary tract. 
The upper limits of CEA levels were determined respectively according to white blood cell counts 
in urine. AIthough， CEA levels were elevated in the poorly-differentiated group and the advanced 
stage group compared to the well-di能 rentiatedand early stage groups， the values were positive in 
only 12 out of 52 ca，ses (23.1%). These values s巴emedto be low compared to other reports. 
s2-MG !evels increased significantly in the poorly-differentiated and advanced stage groups. 
However， most cases in the above groups were complicated with pyelonephritis or renal impairment. 
1 t is suggested that the urinary ，82・MGsecretion from cancer itself is not so significant. 
The diagnostic accuracy of ferritin， CEA， FDP and urine cytology in the same urine samples 
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were 32.6%， 26.7%， 51.7% and 63.0% respectively. Although ferritin and CEA were not as suitab!e 
a param巴teras s2-MG， the combination of these 4 determinations obtained the diagnostic accuracy 
of84.8%. Therefore， the combination ofthose determinations was seemed to be useful in the detection 
of the urinary tract cancer. 






ferritin， carcinoembryonic antigen (CEA)， s2-micro-
globulin (ん-MG) の有用性について尿中 fibrinj











metric assay (IRMA) kit “スパックフェリチン"を
使用した. その詳細についてはすでに報告している
ので円 ここでは省略するが， 30 ngjml以上を異常
{直とした.
2 )尿中 carcinoembryonicantigen (CEA) 
尿中 CEAについては Abbott社製 enzymeim-
















4)尿中 fibrinjfibrinogendegradation products 
(FDP) 
帝国臓器製薬製 FDPLkit R.て測定し， 棚橋の報
告4)!ζ準じ 0.5μgjml以上を異常値とした. なお尿
中赤血球， 白血球数lOjphf以上の症例は dropout 
とした.




1 histological gradeおよび clinicalstage との関
Table 1. Summary of cases 
WelJ Poorly Early Advanced 
dif. dif. stage stage 
group group group group 
1 )Renal adenooarcinoma 3 3 
(4oases) 
Untreated case 4 
2)Renal pelvic and ureteral 4 3 4 3 
oancer (7 cases) 
U ntreated case 7 
3)Bladder cancer (34 cases) 21 13 25 9 
Untreated case 22* 
Recurrent case 12 
* Recurrence was noted in 5 oases for follow-up periods 
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Fig. 1. Upper 1imit of norma1 urinary CEA 1evels in ma1es and 
fema1es according to RBC and WBC counts in urine 
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陽性率は ferritin15/46例 (32.6%)，FDP 15/29例
(51. 7%)， 尿細胞診29/46例 (63.0%)であり，
ferritinはスクリーニングには適さえEいと考えられた.
また FDPは尿中赤血球， 白血球数 IO/hpf以上の








histological grade については Brodersの分類5う
cIinical stageについては Jewettらの分類6)を参考に
してそれぞれ便宜上 weIIdifferentiated group (well 
群)， poorIy differentiated group (poor群)， earIy 
stage group (early群)， advanced stage group (ad-
vanced群)に大別した.
まず尿中 ferritinに関してであるが， well群の 18.1
土5.80ngfml (mean土S.E.) に比し poor群 116土
28.2 ngfmlと有意な上昇を認めた. この内，・， 0印
の腎孟尿管癌および上部尿路に浸潤を認める跨脱癌症
例で12/14例 (87.5%)が高値を示した.clinical stage 
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• urine CEAp儲 ilive





• urine FDP P偶 itive



































































Fig. 6. Comparison of urinary ferritin， CEA and 
cytology for patients with urinary tract 
cancer ln parameter 
lV m ロ工マ
Fig. 5. Comparison of urinary ferritin， FDP 
and cytology for patients with urinary 
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classが高くなるほど陽性例が増加する傾向がみられ 著者の前回の検討的で、は清澄尿でのみ検討し，正常
た. 上限を 6ngfm1と設定したため， 諸家の報告と同様
考 睦J耳、
まず尿中 ferritinについてであるが， 尿中 ferritin
l乙関する検討は非常に少なし原著としては血液疾患
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慢性肝疾患には 1日1回， 40m 1を静脈内に注射。
年齢，症状により適宜増減。
包装 20ml5管・ 30管， 5ml5管・ 50管， 2ml1O管・ 100管
※使用上の注意は，製品の添付文書をご参照下きい。
-内服療法には ~LI普'D=九二号
包装 1000錠， 5000錠
材鐙ミノファーゲン製薬本舗:(干160)東京都新宿区四谷3-2-7
